Suberoylanilide Hydroxyamic Acid Modification of Chromatin Architecture Affects DNA Break Formation and Repair

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 2, 2010, Pages 566-573

  Singh, Sheetal ^a   Le, Hongan ^a   Shih, Shyh Jen ^a   Ho, Bay ^a   Vaughan, Andrew T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

DNA double strand breaks; DNA rearrangements; Radiosensitizer; SAHA; Sublethal damage repair

Indexed keywords

ACID MODIFICATION; BREAKPOINT; CELL LINES; CELL SURVIVAL; CHROMOSOMAL REARRANGEMENT; CLONOGENIC SURVIVAL; DAMAGE REPAIR; DNA BREAKS; DNA CLEAVAGE; DNA STRAND BREAK; DOSE ENHANCEMENT FACTORS; DOUBLE-STRAND BREAKS; HISTONE DEACETYLASES; INVERSE PCR; LIGATION-MEDIATED PCR; MOLECULAR LEVELS; RADIATION-INDUCED; RADIOSENSITIZERS; SITE-SPECIFIC;

ACIDS; CELL CULTURE; DNA; REPAIR;

GENES;

ANTIBODY; DOUBLE STRANDED DNA; RADIOSENSITIZING AGENT; VORINOSTAT;

ARTICLE; CELL LINE; CELL STRAIN MCF 7; CELL STRAIN SCC 25; CELL STRAIN TK6; CELL SURVIVAL; CHROMATIN STRUCTURE; CHROMOSOME 11Q; CHROMOSOME REARRANGEMENT; CLONOGENESIS; CONTROLLED STUDY; DNA CLEAVAGE; DNA FRAGMENTATION; DNA REPAIR; DNA STRAND BREAKAGE; DRUG EFFICACY; GENE REARRANGEMENT; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN MODIFICATION; SEQUENCE HOMOLOGY;

ACETYLATION; CASPASE 3; CELL LINE; CELL SURVIVAL; CHROMATIN; CHROMOSOMES, HUMAN, PAIR 11; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; ENZYME ACTIVATION; GENE REARRANGEMENT; HISTONES; HUMANS; HYDROXAMIC ACIDS; RADIATION-SENSITIZING AGENTS;

EID: 73649096553     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.08.031     Document Type: Article

References (36)

1. Tsai J.Y., Iannitti D.A., and Safran H. Combined modality therapy for pancreatic cancer. Semin Oncol 30 (2003) 71-79
2. Richon V.M. Cancer biology: Mechanism of antitumour action of vorinostat (suberoylanilide hydrosamic acid), a novel histone deacetylase inhibitor. Br J Cancer 95 (2006) S2-S6
3. Chinnaiyan P., Vallabhaneni G., Armstrong E., et al. Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62 (2005) 223-229
4. Jung M., Velena A., Chen B., et al. Novel HDAC inhibitors with radiosensitizing properties. Radiat Res 163 (2005) 488-493
5. Munshi A., Tanaka T., Hobbs M.L., et al. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 5 (2006) 1967-1974
6. Zhang Y., Jung M., and Dritschilo A. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 161 (2004) 667-674
7. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 (2000) 41-45
8. Kim G.D., Choi Y.H., Dimtchev A., et al. Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. J Biol Chem 274 (1999) 31127-31130
9. Ju R., and Muller M.T. Histone deacetylase inhibitors activate p21(WAF1) expression via ATM. Cancer Res 63 (2003) 2891-2897
10. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5 (2006) 769-784
11. Marks P.A., Richon V.M., and Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92 (2000) 1210-1216
12. Munster P.N., Troso-Sandoval T., Rosen N., et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61 (2001) 8492-8497
13. Marks P., Rifkind R.A., Richon V.M., et al. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1 (2001) 194-202
14. Mann B.S., Johnson J.R., Cohen M.H., et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12 (2007) 1247-1252
15. Crump M., Coiffier B., Jacobsen E.D., et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 19 (2008) 964-969
16. Luu T.H., Morgan R.J., Leong L., et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California Cancer Consortium study. Clin Cancer Res 14 (2008) 7138-7142
17. O'Connor O.A., Heaney M.L., Schwartz L., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24 (2006) 166-173
18. Shiozawa K., Nakanishi T., Tan M., et al. Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res 15 (2009) 1698-1707
19. Richon V.M., Garcia-Vargas J., and Hardwick J.S. Development of vorinostat: Current applications and future perspectives for cancer therapy. Cancer Lett 280 (2009) 201-210
20. Betti C.J., Villalobos M.J., Diaz M.O., et al. Apoptotic triggers initiate translocations within the MLL gene involving the nonhomologous end joining repair system. Cancer Res 61 (2001) 4550-4555
21. Betti C.J., Villalobos M.J., Jiang Q., et al. Cleavage of the MLL gene by activators of apoptosis is independent of topoisomerase II activity. Leukemia 19 (2005) 2289-2295
22. Libura J., Slater D.J., Felix C.A., et al. Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion. Blood 105 (2005) 2124-2131
23. Yang C., Betti C., Singh S., et al. Impaired NHEJ function in multiple myeloma. Mutat Res 660 (2009) 66-73
24. Le H., Singh S., Shih S.J., et al. Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding. Genes Chromosomes Cancer (2009)
25. Marschalek R. Etoposide-treatment and MLL rearrangements. Eur J Haematol 81 (2008) 481-482
26. Pastwa E., and Blasiak J. Non-homologous DNA end joining. Acta Biochim Pol 50 (2003) 891-908
27. Frew A.J., Johnstone R.W., and Bolden J.E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 280 (2009) 125-133
28. Hrzenjak A., Kremser M.L., Strohmeier B., et al. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol 216 (2008) 495-504
29. Elkind M.M., Sutton-Gilbert H., Moses W.B., et al. Sub-lethal and lethal radiation damage. Nature 214 (1967) 1088-1092
30. Vakifahmetoglu H., Olsson M., and Zhivotovsky B. Death through a tragedy: Mitotic catastrophe. Cell Death Differ 15 (2008) 1153-1162
31. Gisselsson D., Shao C., Tuck-Muller C.M., et al. Interphase chromosomal abnormalities and mitotic missegregation of hypomethylated sequences in ICF syndrome cells. Chromosoma 114 (2005) 118-126
32. Roninson I.B., Broude E.V., and Chang B.D. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Update 4 (2001) 303-313
33. Darroudi F., Bezrookove V., Fomina J., et al. Insights into the sites of X ray and neutron induced chromosomal aberrations in human lymphocytes using COBRA-MFISH. Radiat Prot Dosimetry 99 (2002) 189-192
34. Schmid E., Braselmann H., and Nahrstedt U. Comparison of gamma-ray induced dicentric yields in human lymphocytes measured by conventional analysis and FISH. Mutat Res 348 (1995) 125-130
35. Schroder H., and Heimers A. Chromosome aberrations induced in human lymphocytes by in vitro and in vivo X-rays. Mutat Res 517 (2002) 167-172
36. Zaider M., and Rossi H.H. Dual radiation action and the initial slope of survival curves. Radiat Res 8 Suppl. (1985) S68-S76